Gnathodiaphyseal Dysplasia (GDD) — Comprehensive Research Report

Prepared: 21 August 2026 · Target: Gnathodiaphyseal dysplasia · MONDO:0008151 · Category: Mendelian (autosomal dominant, monogenic — ANO5)

Evidence-quality note up front. GDD is an ultra-rare disorder with roughly 100–110 clinically described individuals in the entire literature. Almost all clinical content below rests on case reports and small pedigrees; there are no cohort studies, no clinical trials, no registry data, and no natural-history study. Mechanistic content rests almost entirely on mouse models and heterologous cell expression — and, as detailed in §6 and §15, the mouse models actively disagree with one another. Sections where the honest answer is "not available" are marked as such rather than filled with inference.

1. Disease Information

Overview

Gnathodiaphyseal dysplasia is a rare autosomal dominant generalized skeletal syndrome defined by the co-occurrence of three features: fibro-osseous (cemento-osseous) lesions of the jawbones, generalized bone fragility with recurrent fractures, and bowing plus diaphyseal cortical thickening/sclerosis of the tubular bones. Riminucci et al. established it as a discrete nosological entity in 2001, distinguishing it from polyostotic fibrous dysplasia; the jaw lesions are cemento-ossifying fibromas with a prominent psammomatoid body component, and — importantly for the name — osteosclerosis is not a feature of the jaw lesions themselves, which is why the entity was renamed from "gnathodiaphyseal sclerosis" (PMID:11547842).

The canonical description from the gene-discovery paper: "Gnathodiaphyseal dysplasia (GDD) is a rare skeletal syndrome characterized by bone fragility, sclerosis of tubular bones, and cemento-osseous lesions of the jawbone." (Tsutsumi et al., Am J Hum Genet 2004; PMID:15124103, DOI 10.1086/421527)

A defining and clinically underappreciated feature is susceptibility to purulent osteomyelitis of the jaws, typically emerging in adult life, often after dental extraction, with purulent discharge from gums, tooth mobility, tooth loss, and poor extraction-site healing (PMID:28176803).

Key identifiers

Synonyms and alternative names

• GDD (standard abbreviation)
• Gnathodiaphyseal sclerosis / hereditary gnathodiaphyseal sclerosis (historical; abandoned because jaw lesions are not sclerotic)
• Osteogenesis imperfecta with unusual skeletal lesions (historical; how the original Japanese family was labelled)
• Osteogenesis imperfecta, Levin type / Levin syndrome 2
• Familial gigantiform cementoma (FGC) and familial florid cemento-osseous dysplasia (FFCOD) — see §10; these are increasingly regarded as allelic/atypical variants of GDD rather than separate entities (PMID:37649308, PMID:27216912, PMID:42361776)

Data provenance

All information below is disease-level, derived from published case reports, pedigrees, and functional studies. There is no EHR-derived, registry-derived, or claims-derived data on GDD. The largest structured clinical dataset in existence is the literature aggregation in Cuvelier et al. 2024 (PMID:38922934): 108 clinically diagnosed individuals across 25 families, of whom 67 individuals from 21 families had molecular confirmation.

2. Etiology

Disease causal factors

GDD is monogenic and fully genetic. It is caused by heterozygous (monoallelic) variants in ANO5 (anoctamin-5 / TMEM16E / GDD1) at chromosome 11p14.3. There is no known environmental, infectious, or multifactorial contribution to disease causation.

Historical trail of causal establishment: 1. Linkage — Tsutsumi et al. mapped the locus to an 8.7 cM interval at 11p14.3–15.1 in a four-generation Japanese family, establishing GDD "as a new and distinct disease entity from other systemic bone diseases" (J Bone Miner Res 2003; PMID:12619924). 2. Gene identification — "In the critical region determined by recombination mapping, we identified a novel gene (GDD1) that encodes a 913-amino-acid protein containing eight putative transmembrane-spanning domains. Two missense mutations (C356R and C356G) of GDD1 were identified in the two families with GDD..." (PMID:15124103)

Genetic risk factors

• Causal variants: heterozygous ANO5 missense variants (and rare in-frame indels/frameshifts), concentrated in exons 7, 11, 15, and 16. See §4 for the full variant catalogue.
• Susceptibility loci / GWAS: none. No GWAS has been or realistically could be performed on a disease this rare.
• Modifier genes: Essentially unstudied. One tentative report suggested COL5A1 variants as potential modifiers in two affected siblings with divergent severity (cited in PMID:28176803). A COL6A3 variant (c.4604G>A; p.Arg1535His) found in one proband with combined myopathy+GDD was explicitly excluded as contributory, because it was absent in other affected family members (PMID:34291158). Treat "modifier genes" as an open question, not an established finding.

Environmental risk factors

None established for disease causation. However, several environmental/behavioural factors clearly act as precipitants or exacerbators of specific manifestations and should be modeled as such rather than as risk factors for the disease:

• Minimal trauma precipitates fractures — one patient sustained "five fractures, all occurring as a result of minimal trauma" (PMID:28176803).
• Dental extraction and oral surgery precipitate jaw osteomyelitis and non-healing extraction sites (PMID:28176803, PMID:29518808).
• Physical exertion precipitates rhabdomyolysis and compartment syndrome in the rare combined muscle+bone phenotype (PMID:34291158).
• Vitamin D deficiency was documented in most members of one Chinese GDD pedigree and is plausibly an aggravating cofactor for the low-bone-mass subtype (PMID:35982081).

Protective factors

No genetic or environmental protective factors have been identified. No protective ANO5 alleles are described. gnomAD/ExAC data are informative only in the negative direction: GDD-causing variants are absent from population databases (see §4).

Gene–environment interactions

Two interactions have functional support:

1. Mechanical/membrane challenge unmasks Ano5 dependency. Rolvien et al. found no skeletal or muscular phenotype in Ano5 knock-in or knockout mice under homeostatic conditions and reasoned: "it is conceivable that the function of Ano5 is only required, if there is cell membrane damage. Potentially, a challenge, such as muscular training, is required to induce an observable phenotype that is not present under homeostatic conditions." (PMID:32455153) — this is a genotype × mechanical-challenge interaction hypothesis, not yet demonstrated in bone.
2. Age × genotype. Li et al. argued that mouse studies using 12–24-week-old animals mask the phenotype because "the onset of GDD occurs at a very young age, mostly in juveniles between 10 and 16 years old," and that osteoporosis-like signals are obscured by murine ageing changes (PMID:35982081). Human data support an age effect in the other direction: elderly GDD patients maintain normal-to-increased bone mass because their low osteoclast activity protects against age-related bone loss (PMID:35982081).

3. Phenotypes

3a. Frequency data — the single best source

The only quantitative frequency data for GDD come from the systematic literature aggregation of 108 clinically diagnosed individuals in 25 families (67 molecularly confirmed, 21 families) in Cuvelier et al., Prenatal Diagnosis 2024 (PMID:38922934; DOI 10.1002/pd.6631):

✓ = HPO label verified against the repository's local cache/hp/terms.csv.

Caution on interpreting these percentages. They are literature-derived, so they are ascertainment-biased in two opposing directions: jaw lesions are over-represented because most patients reach diagnosis through a maxillofacial surgeon, while mild/asymptomatic carriers within reported pedigrees are systematically under-phenotyped. They should be recorded with evidence_source: HUMAN_CLINICAL and a note that they are aggregated case-report frequencies, not cohort frequencies.

3b. Craniofacial / gnathic phenotypes

Cemento-osseous jaw lesions are the disease's signature. Radiographically they present as "multiple lobular or amorphous radiopacities in the tooth-bearing segments of the maxilla and mandible, and a cotton-wool-like pattern in the alveolar regions" (PMID:28176803). Histologically: "Histopathological descriptions of tissue from GDD lesions note fibrous tissue with irregular acellular mineralized masses and small rounded spherical mineralized bodies (psammomatoid bodies)" (PMID:28176803).

• Severity: highly variable — from asymptomatic radiographic findings to a 7.1 × 5.6 × 5.5 cm anterior mandibular mass requiring angle-to-angle segmental mandibular resection in a 15-year-old (PMID:28176803).
• Progression: progressive and recurrent. One 4-year-old showed "symmetric anterior-posterior expansion of the maxilla from 2.8 to 5.1 cm over 4 months" and by age 1 year "was no longer able to close his mouth" (PMID:28176803). Recurrence after incomplete resection is characteristic (PMID:37649308).
• Onset: the 41-year radiographic follow-up study (PMID:40861765) is the best natural-history document available: no jawbone symptoms at age 3 despite already-visible diaphyseal cortical widening; slight alveolar sclerosis at age 9; clearly increased sclerotic-mass density after completion of secondary dentition at 14. Conclusion: "the onset of the jawbone lesion had already appeared after the mixed dentition stage, and the sclerotic mass developed with age."
• Related terms: HP:0000326 Abnormal maxilla morphology ✓; HP:0000324 Facial asymmetry ✓; HP:0002797 Osteolysis ✓

Jaw osteomyelitis — HP:0007626 Mandibular osteomyelitis ✓ / HP:0002754 Osteomyelitis ✓. "A number of GDD patients develop osteomyelitis in the oral cavity with an increased propensity for bacterial infections, resulting in the secretion of purulent exudate (pus) from infected lesions" (PMID:28176803). Typically adult-onset; the Chinese proband had "a more than 30-year history of propensity for jaw infections."

Tooth loss, impaction, and displacement. In one pedigree, patients had "multiple impacted teeth in the nasal side of the maxillary sinus and the inferior margin of the mandible," and impacted teeth were the presenting sign in two children aged 7–8 (PMID:35982081).

3c. Appendicular / axial skeletal phenotypes

• Bone fragility with recurrent fractures. Onset "appears to be more common in the second decade of life," but the range is extraordinary: prenatal (bilateral femur fractures at 20 weeks gestation, PMID:28176803; multiple diaphyseal fractures of femurs, tibias, upper extremities, ribs and clavicle on fetal autopsy, PMID:38922934), neonatal, childhood, or as late as age 42 (PMID:28176803, PMID:38922934). One proband had "8 fractures in his left forearm and 1 fracture in left femur" between ages 7 and 17 (PMID:34291158).
• Diaphyseal cortical thickening and sclerosis with narrowed medullary canals — "gross thickening of the diaphyseal cortices of long bones with narrow medullary canals" (PMID:28176803). Suggested HP:0005045 Diaphyseal cortical sclerosis (HPO API-sourced; not present in the local term cache — verify with OAK before use).
• Bowing of tibiae/fibulae, femora.
• Vertebral involvement: compression fractures of lumbar vertebrae in infancy (PMID:28176803); "severe osteopenia in cervical spine" (PMID:34291158); "thin and short" vertebral bodies on fetal imaging (PMID:38922934).
• Calvarial involvement: "lacunar skull deformity (Lueckenschaedel)" in one infant (PMID:28176803); calvarial doughnut lesions in an Asian Indian patient, an explicit phenotype expansion (PMID:32902009).
• Bone pain — HP:0002653 ✓; genu varum — HP:0002970 ✓.

3d. The bone-density paradox — two mechanistically distinct subtypes

This is the most important phenotypic subtlety in GDD and is easily mis-curated. Different ANO5 variants produce opposite bone-mass phenotypes:

Li et al. state the framework explicitly: "GOF of TMEM16E protein results in high-bone-mass phenotype GDD by hyperfunction of PLS with increased osteoblast and osteoclast indices, while LOF of TMEM16E protein causes low-bone-mass phenotype GDD by impaired function of calcium oscillations with decreased osteoblast and osteoclast indices... our results suggest the existence of GDD-sub-entities with high and low BMD phenotypes due to different GOF and LOF mutations and functions." (PMID:35982081)

Curation implication: a KB entry that records a single INCREASED or DECREASED modifier on bone mineral density will be wrong for half of patients. This is a genuine has_subtypes situation, and the assignment is by variant class, not by clinical convention.

3e. Laboratory abnormalities

• Elevated serum alkaline phosphatase (ALP) — documented in GDD patients and reproduced in both Ano5^−/− and Ano5^KI/KI (Cys360Tyr) mice: "Serum alkaline phosphatase (ALP) levels were elevated in Ano5-/- mice as in GDD patients" (PMID:30712070); "Serum ALP levels were elevated in Ano5KI/KI mice as in GDD patients with p.Cys360Tyr mutation" (PMID:34841576). "A slight increase in alkaline phosphatase levels in the blood" was seen in an FGC patient (PMID:37649308). (No HPO label for elevated ALP was found in the local cache — look up "Elevated circulating alkaline phosphatase concentration" with OAK before binding.)
• Bone turnover markers: direction is subtype-dependent — see §3d. Markers used: P1NP, N-MID osteocalcin, β-CTx (PMID:35982081).
• 25-OH vitamin D deficiency in most members of one pedigree (PMID:35982081).
• Elevated creatine kinase — HP:0003236 ✓ — only in the rare combined muscle+bone phenotype; peak CK values of 8,000, 6,000, and 25,000 IU/L in three members of one kindred (PMID:34291158).

3f. Muscle phenotypes — a genuinely contested boundary

The textbook position is that ANO5 bone and muscle diseases are non-overlapping: "Pathogenic ANO5 variants cause 2 distinct disorders with no overlapping features." (PMID:34291158, intro). Shaibani et al. then broke that rule in the same paper, reporting a large kindred (11 affected) in which the known GDD variant p.Thr513Ile segregated with both phenotypes:

"The unique clinical presentation of recurrent episodes of rhabdomyolysis associated with muscle cramps, hyperCKemia, muscle hypertrophy, with absent or mild muscle weakness, as well as cemento-osseous lesions of the mandible, with or without bone fractures and other skeletal abnormalities... Our data challenge recent results that suggested complete dichotomy of these phenotypes and the proposed loss-of-function and gain-of-function mechanisms for the skeletal and muscle phenotypes, respectively." (PMID:34291158)

Features in that kindred: rhabdomyolysis (HP:0003201 ✓) 3–5×/year lasting 5–7 days, muscle cramps, muscle hypertrophy, and — novel for ANO5 disease — compartment syndrome requiring fasciotomy (four episodes in one 20-year-old, one causing peroneal nerve injury).

3g. Quality of life

No formal QoL instrument (EQ-5D, SF-36, PROMIS) has ever been applied to GDD. Documented functional impacts, per-manifestation:

4. Genetic / Molecular Information

Causal gene

ANO5 (anoctamin 5), also TMEM16E, historically GDD1. - HGNC: hgnc:27337 · NCBI Gene: 203859 · OMIM: 608662 - Locus: 11p14.3; 22 exons (PMID:36292621) - Reference transcript: NM_213599.3 - Protein: 913 amino acids, ~107 kDa; UniProt Q75V66 - Topology: classically described as 8 transmembrane domains with cytoplasmic N- and C-termini (PMID:15124103); revised to 10 membrane-spanning helices following the nhTMEM16 crystal structure (PMID:29124309, PMID:35982081) - Domains: one DUF590 / anoctamin domain; a 35-aa scrambling domain (SCRD); three calcium-binding sites (PMID:36292621, PMID:35982081) - Eight cysteines at positions 342, 353, 356, 360, 369, 601, 606, 804* in the putative extracellular loops are conserved from human to insect and are thought to form intrachain disulfide bonds critical to folding (PMID:28176803)

Catalogue of reported GDD-causing ANO5 variants

All are heterozygous, germline, and predominantly missense. Coordinates on NM_213599.3.

Mutational clustering. Cuvelier et al. summarize: "GDD is caused by variants localized in a few exons, particularly in regions that encode the cytoplasmic or extracellular domains," with cysteines 356 and 360 as hotspots (PMID:38922934). Jin et al. locate them structurally: "all GDD mutations known so far locate in an extracellular domain following the first transmembrane domain or in the 4th putative transmembrane domain" (PMID:28176803).

Variant classification and population frequency

• ACMG classification: GDD variants are consistently classified pathogenic or likely pathogenic (class 4/5). The fetal-case variants were "probably pathogenic (class 4)" (PMID:38922934).
• Allele frequency: GDD variants are absent from all population databases. "These four ANO5 (TMEM16E) variants in GDD patients were absent in dbSNP, 1000Genomes, the Exome Variant Server (~6500 exomes) and the ExAC database." (PMID:28176803). Later studies applied MAF < 0.005 filters against dbSNP138, 1000 Genomes, CG69, EVS and ESP and retained the ANO5 variant (PMID:35982081).
• In silico: consistently "probably damaging" (PolyPhen-2), "damaging"/"deleterious" (SIFT, score 0), "disease-causing" (MutationTaster, score 1), CADD 28 for C356Y (PMID:28176803, PMID:37649308).
• Somatic vs germline: germline in all cases. Zhou et al. sequenced both tumour tissue and peripheral blood in FGC patients and found the same heterozygous variant in both — i.e. constitutional, not a somatic second-hit tumour mechanism (PMID:37649308). This is a key contrast with fibrous dysplasia (somatic GNAS).
• De novo rate: substantial. De novo variants are documented in at least six independent probands and correlate with severity: "De novo variants correlated with more severe phenotypes and earlier onset, while familial variants showed broader age ranges." (PMID:38922934)

Functional consequence — GOF vs LOF, an unresolved and consequential dispute

This is the central mechanistic controversy in GDD and must be represented as such, not collapsed into a single answer.

The GOF position (biophysics). Di Zanni et al. provided the first direct functional demonstration:

"While the activity of wild-type TMEM16E depended on elevated cytosolic Ca2+ levels, a mutant form carrying the GDD-causing T513I substitution showed PLS and large time-dependent ion currents even at low cytosolic Ca2+ concentrations... these data provide the first direct demonstration of Ca2+-dependent PLS activity for TMEM16E and suggest a gain-of-function phenotype related to a GDD mutation." (PMID:29124309, DOI 10.1007/s00018-017-2704-9)

Quantitatively: wild-type TMEM16E activation threshold was +125.2 ± 6.1 mV at zero Ca²⁺ and +88.1 ± 2.8 mV at 3 µM Ca²⁺; the T513I mutant activated at +82.3 ± 4.1 mV at zero Ca²⁺ — i.e. mutant activity at zero calcium equalled wild-type activity at 3 µM. Wild-type Ca²⁺ dependence: half-maximal 2.9 µM, Hill coefficient 1.5. The follow-up study extended this across variants: "MD mutations are associated to loss-of-function and GDD mutations to gain-of-function phenotypes, confirming conjectures made on the basis of inheritance modes." (PMID:32112655)

The LOF position (protein abundance and cell biology). Jin et al. found "In vitro studies overexpressing GDD mutations (p.Cys356Tyr and p.Cys360Tyr) showed significantly reduced ANO5 protein" (PMID:28176803). Li et al. documented a frameshift-insertion GDD family with reduced TMEM16E protein in PBMCs and argued: "our results suggest that ANO5 is dosage-sensitive and that LOF of the TMEM16E protein caused by the heterozygous ANO5 mutation in one allele is partly compensated by another normally functional allele." (PMID:35982081)

Why both can be true. Different variant classes plausibly act differently — a folding-destabilizing cysteine substitution (C356Y/C360Y, degraded via the proteasome) is not the same lesion as a scrambling-domain-proximal substitution that renders the protein constitutively active (T513I). This maps directly onto the two bone-mass subtypes in §3d. A KB entry should curate this as competing mechanistic_hypotheses with distinct hypothesis_group_ids, not as a settled fact.

Note also that Jin et al. argue against pure haploinsufficiency on two grounds: "The lack of an obvious skeletal phenotype in Ano5 knock-out mice argue against a dose effect" and the existence of recessive truncating LGMD alleles in the same region (PMID:28176803).

Epigenetics

No DNA methylation, histone-modification, or chromatin study of GDD exists. The only epigenetic-adjacent finding is post-transcriptional: Ano5 deficiency "notably inhibited miR-34c-5p expression," de-repressing its target Klf4 (PMID:40508076) — see §6.

Chromosomal abnormalities

Not applicable. GDD is not caused by aneuploidy, translocation, inversion, or CNV. Chromosomal microarray, karyotype, and FISH have no diagnostic role.

5. Environmental Information

• Environmental toxicant/occupational factors: none identified. No CTD entries link environmental chemicals to GDD.
• Lifestyle factors: no established dietary, smoking, alcohol, or activity association with disease risk. Exercise is relevant only as a rhabdomyolysis trigger in the combined phenotype (PMID:34291158), and physical activity/mechanical loading as a fracture precipitant.
• Infectious agents: GDD is not an infectious disease. However, secondary bacterial infection of jaw lesions is a defining complication — purulent osteomyelitis of the mandible and maxilla (PMID:28176803, PMID:29518808). Causative organisms are not systematically speciated in the literature; expect the usual odontogenic/osteomyelitis flora. Model this as a downstream complication node, not an etiological factor.

6. Mechanism / Pathophysiology

6a. Normal ANO5/TMEM16E biology

Expression. ANO5 is highly expressed in skeletal and cardiac muscle, and — critical for GDD — in growth-plate chondrocytes and osteoblasts (PMID:17418107, PMID:34291158). Mizuta et al.: "GDD1 protein is an integral membrane glycoprotein that resides predominantly in intracellular vesicles." During early embryogenesis it is expressed in myotomal and sclerotomal somites (PMID:28176803). It is also expressed in human periodontal ligament cells (PMID:29124309).

Subcellular localization. Predominantly endoplasmic reticulum — co-localizing with calreticulin and CellLight ER-RFP markers (PMID:15124103, PMID:28176803, PMID:29124309) — with partial plasma-membrane localization at high expression levels, which is what enabled the electrophysiological characterization (PMID:29124309). GO CC: GO:0005783 endoplasmic reticulum ✓.

Molecular function — three competing/complementary assignments: 1. Ca²⁺-activated chloride channel (CaCC) — the original inference from family membership (GO:1902476 chloride transmembrane transport ✓). This is now largely rejected. Tran et al. noted ANO5 has a threonine rather than a cysteine at position 611, one of three conserved cysteines in true CaCCs (ANO1/ANO2) (cited in PMID:28176803); halide-sensitive YFP assays found no anion transport (PMID:29124309); Ano5-deficient mice showed chloride currents indistinguishable from wild-type (PMID:36292621). 2. Ca²⁺-dependent phospholipid scramblase (PLS) — the currently favoured assignment (GO:0045332 phospholipid translocation ✓). Directly demonstrated by annexin-V binding assays with Ca²⁺-ionophore stimulation (PMID:29124309). "ANO5 functions predominantly in phospholipid scrambling (PLS), which facilitates the movement of phospholipids between the membrane bilayer during various biological processes." (PMID:36292621) 3. ER Ca²⁺ conduit / regulator of intracellular Ca²⁺ transients — "our data support the view that TMEM16E at the ER membrane of bone cells sustains Ca2+ transitions to the cytoplasm" (PMID:35982081) (GO:0070588 calcium ion transmembrane transport ✓; GO:0051209 release of sequestered calcium ion into cytosol ✓).

Note that ion transport may be biophysically real but physiologically irrelevant: Di Zanni et al. observed currents only at >+75 mV, and concluded "Considering furthermore their exclusive activation at highly depolarized membrane potentials, which are unlikely to be experienced by non-excitable cells, one may conclude that ion transport is not among the physiological functions of TMEM16E." (PMID:29124309)

Membrane repair (GO:0001778 plasma membrane repair ✓) is the best-established physiological role, though it is characterized in muscle rather than bone: ANO5 translocates to injured sarcolemma and is required for annexin recruitment to the repair cap (PMID:36292621).

6b. Causal chain — trigger to clinical manifestation

Because of the GOF/LOF split, there are two parallel proximal chains converging on a shared distal phenotype. Both are supported; neither is exclusive.

Chain A — the LOF / low-bone-mass route (best evidenced by PMID:35982081, PMID:40049314, PMID:36989132):

Heterozygous ANO5 destabilizing variant
  → reduced TMEM16E protein (proteasomal degradation)          [MOLECULAR]
  → loss of ER-mediated Ca²⁺ transients; [Ca²⁺]i oscillations
    abolished in osteoblasts, blunted in osteoclasts            [CELLULAR]
  → ┌─ osteoblast arm: ↓WNT1/β-catenin/Dvl2, ↑GSK-3β/Axin1
    │    → ↓Ocn, ↓Spp1, ↓ALP, ↓mineral nodules                  [CELLULAR]
    └─ osteoclast arm: ↓RANKL-induced NFATc1/c-Fos nuclear
         translocation → ↓Trap, ↓Ctsk, ↓Mmp9, ↓Dc-stamp,
         disrupted F-actin ring, ↑ER-stress/CHOP apoptosis      [CELLULAR]
  → coupled suppression of formation AND resorption
    ("vicious cycle" of remodeling arrest)                       [TISSUE]
  → low bone volume, osteopenia, fragility                       [ORGANISM]

Chain B — the GOF / high-bone-mass route (best evidenced by PMID:29124309, PMID:32112655, PMID:27541832, PMID:34841576):

Heterozygous ANO5 GOF variant (e.g. T513I)
  → constitutive, Ca²⁺-independent phospholipid scrambling      [MOLECULAR]
  → aberrant membrane-surface phosphatidylserine exposure;
    loss of cell adhesion, cell rounding                         [CELLULAR]
  → ↑osteoblastogenesis (↑Runx2, Osterix, Col1a1, Ocn),
    hypermineralized matrix; ↓osteoclastogenesis                 [CELLULAR]
  → high-turnover osteosclerosis, cortical thickening,
    narrowed medullary canal                                     [TISSUE]
  → paradoxical fragility despite high mass                      [ORGANISM]

The paradox that unifies them. Both routes produce fragility, whether bone mass is low or high. In the high-mass form the bone is hypermineralized and therefore brittle — Jin et al.: "ANO5 may act as a negative regulator of mineralization and that reduced protein levels due to ANO5 mutations or interactions of instable mutant ANO5 proteins may result in abnormal bone deposition or remodeling with over-mineralization, hyperostosis and brittle bones." (PMID:28176803). This is mechanistically similar to the fragility of osteopetrosis and of COL1A1 C-propeptide-cleavage-site OI (PMID:24891183).

6c. Downstream signalling pathways — a rapidly expanding 2024–2026 literature

Five independent effector pathways have been nominated in the last two years, all downstream of Ano5 disruption in mouse osteoblasts/osteoclasts. They are not mutually exclusive and several intersect at AMPK.

Metabolic changes. Metabolomics + transcriptomics of Ano5^Cys360Tyr knock-in mouse calvarial osteoblasts identified 42 differential metabolites (amino acid and pyrimidine metabolism; endocrine/other-factor-regulated calcium reabsorption) and 407 differentially expressed genes, converging on cell-cycle progression (Mki67, Ccnb1, Ccna2 up) and calcium signalling (Cacna1, Slc8a1, Cyp27b1 up), with higher calcium content in mineral nodules by SEM-EDS (PMID:36742392).

6d. Protein dysfunction

• Misfolding and instability. GDD cysteine mutants "fold with low efficiency and appear to be unstable and rapidly degraded via proteasomal degradation" (cited in PMID:28176803). Western blot and immunofluorescence confirm reduced mutant protein despite higher construct copy number (PMID:28176803).
• Structural modelling. AlphaFold2 modelling of C356Y showed low global deviation (RMSD 0.256) but local distortion: residues Lys847/Phe848/Leu849 form a helix in wild type and a loop in the mutant (PMID:37649308).
• Cellular consequence of aberrant activity. HEK293 cells expressing GDD mutants "typically became round-shaped and displayed decreased cell adhesion," and Di Zanni et al. showed "the gradual changes in HEK293 cell morphology observed upon expression of TMEM16E/ANO5GDD mutants are a consequence of aberrant protein activity" (PMID:29124309, PMID:32112655).

6e. Immune system involvement

GDD is not an autoimmune or immunodeficiency disorder. The only immune dimension is (a) the propensity to bacterial jaw osteomyelitis (§5) and (b) the fact that osteoclasts are monocyte/macrophage-lineage cells (CL:0000235 macrophage ✓), so RANKL–NFATc1–NF-κB signalling — canonically an immune pathway — is the disease's core osteoclast axis.

6f. Tissue damage mechanisms

Not ischemia, fibrosis (in the classical sense), or oxidative stress. The dominant mechanism is dysregulated bone remodeling (GO:0046849 bone remodeling ✓) with abnormal matrix mineralization (GO:0030282 bone mineralization ✓), plus fibro-osseous replacement of normal jaw architecture: "normal cancellous bones of the jaw were structurally destroyed and poorly mineralized, occupied by a large amount of fibrous tissue and cementum, leading to fibrous cementum-like lesions" (PMID:35982081). ER stress and CHOP-mediated apoptosis are the newest addition (PMID:40049314).

6g. Cell types and processes — ontology suggestions

Cell types (all CL labels verified against local cache): - CL:0000062 osteoblast — primary effector cell; both mouse calvarial osteoblast (mCOB) and BMSC-derived - CL:0000092 osteoclast — the more severely affected lineage in LOF models - CL:0000137 osteocyte - CL:0000138 chondrocyte — growth-plate expression (PMID:17418107) - CL:0000057 fibroblast — the fibroblastic stroma of jaw lesions - CL:0000061 cementoblast — the cementum-like deposits are the disease's histological signature - CL:0000235 macrophage — BMM osteoclast precursor - CL:0000594 skeletal muscle satellite cell — relevant only to the muscle arm

Biological processes (all GO labels verified): GO:0001649 osteoblast differentiation · GO:0030316 osteoclast differentiation · GO:0001503 ossification · GO:0030282 bone mineralization · GO:0045453 bone resorption · GO:0046849 bone remodeling · GO:0045332 phospholipid translocation · GO:0070588 calcium ion transmembrane transport · GO:0051209 release of sequestered calcium ion into cytosol · GO:0071277 cellular response to calcium ion · GO:0060070 canonical Wnt signaling pathway · GO:0006914 autophagy · GO:0034976 response to endoplasmic reticulum stress · GO:0001778 plasma membrane repair · GO:1902476 chloride transmembrane transport (curate with a caveat — largely refuted)

Cellular component: GO:0005783 endoplasmic reticulum

6h. Molecular profiling status

7. Anatomical Structures Affected

Organ level

Primary: - Mandible — UBERON:0001684 mandible ✓ — the most consistently and severely affected structure - Maxilla — UBERON:0002397 maxilla ✓ - Long tubular bones, diaphyseal regions — UBERON:0004769 diaphysis ✓ — femur, tibia, fibula, radius, ulna, humerus - Bone tissue generally — UBERON:0002481 bone tissue ✓

Secondary / less consistent: vertebrae (compression fractures, osteopenia); ilium; calvarium (doughnut lesions, PMID:32902009; lacunar skull, PMID:28176803); clavicle and ribs (fetal fractures, PMID:38922934); dentition and periodontium.

Body systems: skeletal (primary); dental/stomatognathic (primary); musculoskeletal-muscular — UBERON:0001134 skeletal muscle tissue ✓ — only in the rare combined phenotype.

Explicitly NOT affected: No consistent cardiac, renal, hepatic, neurological, or endocrine involvement in GDD proper. (Cardiac involvement of 10–30% is a feature of the recessive ANO5 muscular dystrophies, not GDD — PMID:36292621. Do not transfer it.)

Tissue and cell level

Connective/skeletal tissue is the target. Jaw lesion histology: "a fibroblastic stroma with variable cellularity and a heterogeneous osseous component composed of woven bone and more cementum-like material" (PMID:35982081); "large eosinophilic masses of cementum-like material interspersed in fibrous background" (PMID:28176803); psammomatoid bodies; "abundant mineralization in the vessel wall" (PMID:37649308).

Subcellular level

• Endoplasmic reticulum (GO:0005783 ✓) — principal ANO5 residence and the locus of the Ca²⁺-transient defect
• Plasma membrane / sarcolemma — partial localization; site of scrambling activity
• Intracellular vesicles (PMID:17418107)
• Mitochondria — secondarily abnormal in Ano5^KI/KI osteoclasts via PGC1β (PMID:41717545)

Lateralization

Bilateral, though often asymmetric in extent. Fetal case: "multiple diaphyseal fractures of the long bones... affecting femurs, tibias, and bilateral upper extremity bones" (PMID:38922934). Jaw lesions are typically multi-quadrant — bilateral maxillary and mandibular — which is a key differentiator from unilateral ossifying fibroma. One patient had "bilateral relatively symmetric, expansile lesions in the maxillary bone" (PMID:28176803).

8. Temporal Development

Onset

Extremely variable — this is a defining feature. Jin et al.: "there appears to be a wide age range in the onset of fibrous lesions of the mandible and severity of fractures." (PMID:28176803)

Documented onsets, earliest to latest: - Prenatal: bilateral femur fractures at 20 weeks gestation (PMID:28176803); fetal bowing detected at 12 weeks and confirmed at 16 weeks (PMID:38922934) - Neonatal: fractures at birth (Levin et al., cited in PMID:28176803) - Infancy: maxillary/mandibular enlargement at 2 months; jaw mass at 13 months (PMID:28176803); jaw protuberance at 6 months in an FGC case (PMID:37649308) - Childhood: most fractures; impacted teeth as presenting sign at ages 7–8 (PMID:35982081) - Adolescence: classic textbook onset — "the onset of fractures appears to be more common in the second decade of life" (PMID:28176803) - Adulthood: jaw lesion first diagnosed at age 21, 43, 62, and 67 in different individuals (PMID:28176803)

HPO records HP:0003621 Juvenile onset for this disease (HPO API-sourced; verify with OAK — not in the repository's local term cache). Orphanet records age of onset as infancy, childhood, and adolescence.

Onset pattern: insidious and chronic for jaw lesions; acute/episodic for fractures.

Progression

GDD is chronic, lifelong, and progressive. There is no spontaneous remission.

The strongest evidence for progression comes from two longitudinal documents: 1. Rolvien et al.'s 3-year follow-up of the S500F patient: DXA BMD Z-score remained stable, but "cortical thickness assessed by HR-pQCT at the distal tibia further increased at one and three years follow-up, which led to values clearly above the age-adjusted reference values." The authors conclude: "These clinical data demonstrate the progressive nature and lack of viable treatment options for this disorder." (PMID:32455153) 2. The 41-year radiographic study (PMID:40861765): diaphyseal cortical widening visible at age 3 before any jaw symptoms; alveolar sclerosis at 9; dense sclerotic mass after secondary dentition at 14; continued development into the fifth decade.

Stages (informal — no consensus staging system exists): - Pre-symptomatic / radiographic-only: diaphyseal cortical widening detectable before jaw involvement (age ~3) - Fracture-predominant: childhood to adolescence - Jaw-lesion-predominant: mixed dentition onward, expansile growth - Complication phase: adult jaw osteomyelitis, tooth loss, non-union fractures, surgical morbidity

Rate: variable; the jaw lesions can grow explosively (maxilla 2.8 → 5.1 cm in 4 months, PMID:28176803) or indolently over decades.

Course pattern: progressive with episodic acute events (fractures, osteomyelitis flares, and — in the combined phenotype — rhabdomyolysis 3–5×/year lasting 5–7 days, PMID:34291158).

Duration: lifelong.

Critical periods

• Mixed-dentition transition (~age 6–14) appears to be the window in which jaw lesions initiate — the single most actionable observation for surveillance timing (PMID:40861765).
• First two decades — peak fracture incidence, and therefore the window in which bone-directed therapy is most likely to matter.
• Any dental extraction is a discrete risk window for osteomyelitis and non-healing.
• The FGC literature describes a three-phase growth pattern for jaw lesions that may transfer: "initial onset at 11–13 years of age, rapid expansion between 14 and 16 years of age, and growth suppression around 18–20 years of age" (PMID:37649308).

Remission

No spontaneous remission. Jaw lesions recur after incomplete resection — "the recurrence rate of FGC is high, and incomplete resection or conservative curettage often leads to more rapid progression of the remaining portion, which does not recur after complete resection" (PMID:37649308).

9. Inheritance and Population

Epidemiology

• Prevalence: <1 / 1,000,000 (Orphanet ORPHA:53697). In dismech PrevalenceClassEnum terms this is BELOW_1_IN_1000000, with measure_type: POINT_PREVALENCE, or arguably CASES_IN_LITERATURE given how the number was derived.
• Cases reported: approximately 108 clinically diagnosed individuals across 25 families, of whom 67 individuals in 21 families have molecular confirmation (PMID:38922934). This is the most defensible case count and should be preferred over vaguer statements.
• Incidence: unknown; no incidence estimate exists.
• MedlinePlus Genetics: "The prevalence of gnathodiaphyseal dysplasia is unknown, but it is thought to be a rare disorder."

Inheritance

• Autosomal dominant — HP:0000006 (HPO API-sourced). Established by four-generation pedigree linkage (PMID:12619924) and repeatedly confirmed by segregation (PMID:28176803, PMID:34291158, PMID:35758145).
• Penetrance: appears high, possibly complete for the radiographic phenotype, but is not formally quantified in any study. In the Shaibani kindred two female carriers reported no muscle symptoms though bone findings were present, and the authors noted "the possibility remains that these 2 female patients have asymptomatic muscle involvement" (PMID:34291158). Record penetrance as not established.
• Expressivity: highly variable, both interfamilial and intrafamilial. Jin et al.: "our findings strongly indicate the association of ANO5 mutations with GDD, and we show that there is considerable clinical variability in patients, even within one family. These differences in expressivity can currently not be explained due to the limited number of patients available for phenotypic/genetic studies." (PMID:28176803) The clearest example: in the Chinese C360Y family, the 73-year-old father had severe jaw disease with no fractures, while his 43-year-old son was much more mildly affected.
• Genetic anticipation: none reported and none expected — GDD is not a repeat-expansion disorder.
• De novo variants: common, and associated with more severe, earlier-onset disease (PMID:38922934). Documented in at least six probands (G518E, S500F, L370_A371ins, A492V, Q_I512insMet, and others).
• Germline mosaicism: raised as a formal possibility but not demonstrated — "The mutation in sporadic patient 1 is either a de novo mutation or due to germline mosaicism." (PMID:28176803)
• Founder effects: none for GDD. (Contrast the recessive ANO5 myopathies, where c.191dupA (p.Asn64LysfsTer15) is a well-established northern European founder allele with 45–75% homozygosity in England, Germany, and Denmark — PMID:36292621. This allele has nothing to do with GDD and must not be transferred into a GDD entry.)
• Consanguinity: not a factor — GDD is dominant.
• Carrier frequency: not applicable to a dominant disorder; heterozygotes are affected.

Population demographics

• Affected populations: no ethnic predilection. Reported in Japanese (original family), African American, Caucasian/American, Chinese/Han, Italian, Russian, Iranian, Asian Indian, and French individuals (PMID:15124103, PMID:28176803, PMID:23047743, PMID:20005074, PMID:35758145, PMID:32902009, PMID:38922934).
• Geographic distribution: worldwide; no endemic clustering.
• Variant geography: C356 substitutions dominate across populations; C360Y in Chinese, C360R in Iranian, T513I in Italian and American kindreds, R597I in a French family. This reflects reporting history rather than any established population structure.
• Sex ratio: no sex bias reported for GDD. Male and female patients appear in comparable numbers across pedigrees. (The 2:1–4:1 male predominance in the literature applies to ANO5 muscular dystrophies, not GDD — PMID:36292621.)
• Age distribution: all ages, with diagnostic peak in childhood/adolescence.

10. Diagnostics

Clinical / laboratory tests

• Serum alkaline phosphatase — often elevated; the most consistently reported biochemical abnormality (PMID:30712070, PMID:34841576, PMID:37649308)
• Bone turnover panel — P1NP, N-MID osteocalcin, β-CTx. Direction is subtype-dependent (elevated in high-turnover S500F disease, PMID:27541832; reduced in low-bone-mass frameshift disease, PMID:35982081)
• 25-OH vitamin D, calcium (PMID:35982081)
• Creatine kinase — only if muscle symptoms are present; can reach 25,000–40,000 IU/L in rhabdomyolysis episodes (PMID:34291158)

Imaging

• Panoramic dental radiography — first-line for jaw lesions; shows "multiple lobular or amorphous radiopacities in the tooth-bearing segments" and "cotton-wool-like pattern in the alveolar regions" (PMID:28176803). This is often how asymptomatic family members are ascertained.
• CT / 3D maxillofacial CT — lesion extent, surgical planning (PMID:35982081)
• Skeletal survey / plain radiography — diaphyseal cortical thickening, narrowed medullary canals, bowing (PMID:34291158)
• DXA — lumbar spine L1–L4 and femoral neck BMD, with age-adjusted Z-scores (paediatric software required in children) (PMID:27541832, PMID:35982081)
• HR-pQCT at the distal tibia — the most sensitive modality for detecting progressive cortical thickening; detected progression over 3 years when DXA was static (PMID:32455153). This is a practically important point: DXA can be falsely reassuring.
• Prenatal: ultrasound (bowing, shortened femurs, growth restriction) and fetal osseous CT to characterize severity and distinguish from differentials (PMID:38922934)

Histopathology

Diagnostic but not pathognomonic. Findings: cemento-ossifying fibroma pattern; fibroblastic stroma with variable cellularity; woven bone plus cementum-like material; psammomatoid bodies; abundant vessel-wall mineralization (PMID:11547842, PMID:28176803, PMID:37649308).

Caution: psammomatoid bodies are not required — the severe G518E case had "benign fibro-osseous lesions resembling cemento-ossifying fibromas of the jaw without psammomatoid bodies" (PMID:29175271).

Genetic testing — the diagnostic gold standard

Recommended approach (per PMID:38922934): 1. Targeted ANO5 sequencing where clinical suspicion is high — prioritize exons 7, 11, 15, 16, with 11 (Cys356/Cys360) highest yield 2. Skeletal dysplasia / osteogenesis imperfecta gene panel where the presentation is ambiguous 3. Trio exome sequencing (ES) — especially valuable prenatally and for apparently sporadic cases, where de novo status must be established 4. Whole genome sequencing (WGS) — has successfully identified GDD variants where panels failed (PMID:30554457)

Sanger confirmation and family segregation analysis are standard.

Not useful: chromosomal microarray, karyotype, FISH, mitochondrial DNA testing, repeat-expansion testing. None has a role in GDD.

Omics-based diagnostics: none validated. No RNA-seq, proteomic, metabolomic, epigenomic, or liquid-biopsy test exists for GDD.

Clinical criteria

There are no formal, published, consensus diagnostic criteria for GDD. Diagnosis is made by the combination of (a) fibro-osseous jaw lesions, (b) bone fragility/fractures, (c) diaphyseal cortical thickening/bowing, plus (d) a pathogenic ANO5 variant. Li et al. describe the pragmatic composite: "When hereditary, histologic and laboratory features were taken into consideration with clinical and radiographic features, GDD was the most appropriate diagnosis." (PMID:35982081)

Differential diagnosis — and a diagnostic-error rate worth curating

GDD is systematically misdiagnosed. "A review of the literature showed that 67% of GDD cases confirmed by molecular testing were initially misdiagnosed." (PMID:30554457) The 2025 surgical report adds: "clinicians are still largely unaware of this entity and continue to label and treat it as a variation of Osteogenesis Imperfecta." (PMID:41193275)

The 2026 WHO-aligned review consolidates the molecular picture: "familial florid cemento-osseous dysplasia, familial gigantiform cementoma and gnathodiaphyseal dysplasia sharing ANO5 mutations" (PMID:42361776). A dismech entry should decide deliberately whether FGC and familial FCOD are has_subtypes of GDD or separate entries with a Grouping — the literature now favours a shared entity.

Screening

• Cascade family screening is the highest-yield strategy: panoramic radiography plus targeted ANO5 sequencing in first-degree relatives. Several probands were identified through a sibling's routine panoramic radiograph (PMID:28176803).
• Newborn screening: not applicable and not proposed.
• Prenatal: GDD should now be on the differential for fetal long-bone bowing and fractures (PMID:38922934) — this is the newest addition to diagnostic practice.

11. Outcome / Prognosis

Survival and mortality

• No survival, life-expectancy, or mortality data exist. No cohort has been followed.
• GDD is generally not life-limiting, but is not uniformly benign: at least one death is recorded — "The patient died from complications related to GDD." (PMID:28176803, describing the R215G sporadic patient originally reported by Riminucci). Cuvelier et al. counsel that "symptoms can be very severe, even fatal" (PMID:38922934).
• Patients survive into at least the eighth decade (a 73-year-old proband, PMID:28176803).

Morbidity and disability

Substantial and predominantly surgical, dental, and orthopaedic: - Repeated jaw debulking/resection, sometimes ≥3 operations in a young child (PMID:28176803) - Mandibular reconstruction with free vascularized fibular graft, titanium plating (PMID:35982081, PMID:30641283) - Below-knee amputation after fracture non-union complicated by osteomyelitis and skin necrosis (PMID:28176803) - Tooth loss and lifelong prosthodontic dependence (PMID:29518808) - Facial disfigurement - Compartment syndrome requiring multiple fasciotomies, with residual peroneal nerve injury (combined phenotype; PMID:34291158)

Quality-of-life instruments: never applied. No EQ-5D, SF-36, or PROMIS data exist for GDD.

Complications

Jaw osteomyelitis with purulent discharge; fracture non-union; post-traumatic limb-length discrepancy; recurrence of jaw lesions after incomplete resection; airway/feeding/speech compromise from jaw expansion; orbital and sinus involvement from maxillary expansion (in one patient the left eyeball was "compressed and anterior and laterally shifted," PMID:35982081).

Recovery potential

None — there is no recovery. Surgical resection can be curative for a given lesion if complete ("does not recur after complete resection," PMID:37649308), but the underlying skeletal disorder is permanent and progressive. Notably, surgical healing itself can be normal: "All of the fibular and mandibular osteotomies were found to be well healed" (PMID:28176803), and internal fixation of an adult tibial shaft fracture achieved "successful callus formation" (PMID:33826556).

Prognostic factors

Only one is established, and it is qualitative: De novo variant status predicts more severe disease and earlier onset, whereas familial variants show broader age ranges (PMID:38922934).

Suggestive but unvalidated: - Very early onset (prenatal/infantile jaw expansion) predicts severe course (PMID:29175271, PMID:28176803) - Variant position may predict bone-mass subtype (§3d) - Two families (p.C356F, p.L370_A371ins) had jaw lesions without fractures — a milder, jaw-restricted presentation (PMID:38922934)

No validated prognostic biomarker exists. ALP and bone turnover markers are diagnostic/monitoring aids, not validated predictors.

12. Treatment

Framing statement to carry into any KB entry: "Currently, there is no cure for GDD, and management of the disorder is focused on symptom relief and prevention of complications." (PMID:38922934). And: "Currently, the clinical treatment of GDD is limited to surgical resection." (PMID:40049314)

Pharmacotherapy

A treatment-strategy warning that belongs in the entry. Li et al. make the subtype-dependence explicit and it cuts the wrong way if ignored: "There are no established guidelines for the management of fracture risk in these patients. Physicians should assess the patient's skeletal status more accurately, understand the mechanisms of drugs, and formulate a treatment plan under consideration of individual differences in patients." (PMID:35982081) Giving an antiresorptive to a low-turnover, low-bone-mass GDD patient, or an osteoanabolic to a high-turnover osteosclerotic one, is mechanistically wrong. Any curated treatment must be scoped to the correct subtype.

Preclinical / experimental therapeutic targets (all mouse or in vitro only — none has entered human trials)

Surgical and interventional

Jaw surgery (NCIT:C16186 Orthopedic Surgical Procedure / NCIT:C15329 Surgical Procedure; therapeutic_modality: SURGERY): - Debulking — the workhorse, but recurrence is the rule with incomplete removal - Segmental mandibulectomy / total mandibulectomy / subtotal or bilateral partial maxillectomy (PMID:28176803, PMID:35982081) - Microsurgical reconstruction — free vascularized fibular graft, titanium reconstruction plate. Marechal et al. flag the specific difficulty: "the challenges of craniofacial reconstruction in GDD due to the diffuse bone anomalies affecting potential flap donor zones and a specific risk for jawbone osteomyelitis" (PMID:30641283) — the donor bone is itself diseased. - Orthognathic surgery — newly demonstrated as feasible: LeFort I advancement plus bilateral sagittal split osteotomy with setback in a 21-year-old, "No complications were seen and 2-year follow-up showed stable dental occlusion. This is the first report describing orthognathic surgery safely performed on a patient with GDD1." (PMID:41193275)

Conservatism principle: Cuvelier et al. recommend surgical debulking "only for a functional problem or aesthetics" given recurrence risk (PMID:38922934).

Fracture surgery: - Intramedullary devices are recommended first-line for paediatric femoral shaft fractures in GDD (PMID:30797234) - Intramedullary nail fixation for bilateral diaphyseal femur fractures (PMID:32455153) - Internal fixation with successful callus formation in the first reported adult case (PMID:33826556)

Supportive and rehabilitative

• Prosthodontic rehabilitation — a 30-year follow-up showed that "despite severe alveolar bone resorption, prosthetic treatment improved patient satisfaction and functional ability, requiring regular adjustments and monitoring" (PMID:29518808). NCIT:C15302 Physical Therapy is not the right term here; look for a dental prosthesis term with OAK.
• Dental care and pain management (PMID:38922934)
• Physical/occupational therapy post-fracture and post-amputation

Pharmacogenomics, gene therapy, cell therapy, RNA therapy, immunotherapy

None exist for GDD. No pharmacogenomic markers; no gene therapy, gene editing, cell therapy, or approved RNA therapeutic. The AAV-miR-34c-5p work (PMID:40508076) is the closest thing to a nucleic-acid therapeutic concept and is preclinical mouse data only.

Clinical trials

No interventional clinical trial for GDD has ever been registered or reported. A ClinicalTrials.gov search for gnathodiaphyseal dysplasia returns nothing usable. Any NCT identifier attributed to GDD should be treated as suspect and verified with just fetch-reference before curation.

Treatment outcomes

No response rates, no systematic adverse-event data. The single reported bisphosphonate course had no efficacy outcome published (PMID:29175271).

13. Prevention

Primary prevention

Disease occurrence cannot be prevented — GDD is a dominantly inherited monogenic condition. The only primary-prevention modalities are reproductive: - Genetic counselling (NCIT:C15240 Genetic Counseling) — 50% transmission risk per pregnancy, which Cuvelier et al. emphasize must be discussed (PMID:38922934) - Preimplantation genetic testing (PGT-M) and prenatal diagnosis — explicitly recommended: "prenatal/pre-implantation diagnosis and medical termination should be discussed with couples" (PMID:38922934)

Secondary prevention (early detection)

• Cascade genetic testing and panoramic radiographic screening of at-risk relatives — the highest-value intervention available, since many carriers are discovered incidentally (PMID:28176803)
• Prenatal ultrasound surveillance in known-affected families, targeting long-bone bowing (100% of prenatal cases) and fractures (33%) (PMID:38922934)
• Timing: given the 41-year natural-history study, initiating dental radiographic surveillance around the mixed-dentition stage is the evidence-aligned choice (PMID:40861765)

Tertiary prevention (complication avoidance)

This is where most practical benefit lies: - Fracture prevention — fall/trauma avoidance, calcium and vitamin D repletion, subtype-appropriate bone-active therapy - Meticulous dental hygiene and conservative dental management — because extraction sites heal poorly and seed osteomyelitis, prophylaxis and avoidance of unnecessary extraction are rational (extrapolated from the osteomyelitis literature in PMID:28176803, PMID:29518808; not formally studied) - Complete rather than partial lesion resection where surgery is indicated, to avoid accelerated regrowth (PMID:37649308) - Obstetric planning in affected pregnant patients — vitamin D/calcium supplementation and a documented discussion of caesarean delivery based on disease severity (PMID:38922934) - In the combined muscle+bone phenotype, avoiding overexertion to prevent rhabdomyolysis and compartment syndrome (PMID:34291158, PMID:36292621)

Immunization, public health, environmental interventions

Not applicable. No vaccine strategy, no population-level public-health intervention, and no environmental risk factor to modify.

14. Other Species / Natural Disease

Taxonomy and orthologues

• Ano5 is present in mouse (Mus musculus, NCBITaxon:10090), rat, rabbit (Oryctolagus cuniculus, NCBITaxon:9986), zebrafish (Danio rerio, NCBITaxon:7955), fruit fly (Drosophila melanogaster, NCBITaxon:7227), and mosquito — the Cys356 residue is "evolutionarily conserved among human, mouse, zebrafish, fruit fly, and mosquito" (PMID:15124103).
• Mouse Ano5: NCBI Gene ID 233246. Human ANO5: NCBI Gene ID 203859.
• Conservation caveats that matter for model design: Thr513 is not strictly conserved across vertebrate ANO5 orthologues (some carry alanine) — PMID:29124309. And Ser500 is a threonine in mouse, meaning the murine "equivalent" of p.S500F is p.T491F, a chemically different substitution. Li et al. argue this may explain that model's failure: "the amino acid sequence is not conserved between humans and mice at that mutation site... it is possible that Ano5 KI mice with p.T491F amino acid exchange did not display alterations in skeletal microarchitecture" (PMID:35982081).

Natural disease in other species

No naturally occurring GDD has been reported in any non-human species. No OMIA entry corresponds to gnathodiaphyseal dysplasia. There is no known veterinary counterpart, no breed predisposition, and therefore no VBO annotation applies.

Comparative biology

• The eight extracellular-loop cysteines are conserved across humans, teleosts, and insects (PMID:28176803).
• The functional divergence within the TMEM16 family is itself instructive: TMEM16A/B are Ca²⁺-activated chloride channels, TMEM16C/D/F/G/J are scramblases, and the T513-equivalent position "has divergent roles in phospholipid scrambling and chloride channel activity of TMEM16 family members" — introducing the same substitution into TMEM16B barely affected it (PMID:29124309).
• The strongest comparative-biology conclusion is negative: "Ano5 is dispensable for bone homeostasis in mice, at least under unchallenged conditions, and... these animals may not present the most adequate model to study the physiological role of Anoctamin 5." (PMID:32455153)

Transmission

No zoonotic potential and no cross-species susceptibility — GDD is a germline genetic disorder, not transmissible.

15. Model Organisms

The central problem: the mouse models contradict each other

This is the single most important thing to record about GDD models, and it maps directly onto dismech's HUMAN_MODEL_MISMATCH discussion kind rather than a generic knowledge gap — evidence exists in models, and it is the translational validity that is in dispute.

The authors themselves name the contradiction. Rolvien et al.: "our results are in apparent contradiction to another study, where Ano5-deficient mice recapitulated some aspects of GDD... it is quite surprising that a loss of Ano5 mimics the phenotype of GDD, especially in the light of the aforementioned study suggesting that GDD-causing mutations convey a gain-of-function... Therefore, we believe that further research is required to resolve this apparent contradiction." (PMID:32455153)

Shaibani et al. summarize the whole picture: "mouse models yielded conflicting results, including sarcolemma repair abnormalities and defective myoblast regeneration and fusion, lack of muscle phenotype, GDD phenotype in Ano5-knockout mice, as well as absence of skeletal phenotype in a knock-in model of a GDD-related mutation." (PMID:34291158)

Candidate explanations offered in the literature (none resolved): 1. Animal age — GDD onsets at 10–16 years in humans; 12–24-week mice are already adult/middle-aged and skeletal signals may be masked (PMID:35982081) 2. Residual function in one deficiency model vs complete loss in another (PMID:32455153) 3. Species-divergent residue at the mutated site (Ser vs Thr at human 500 / mouse 491) (PMID:35982081) 4. Unchallenged conditions — Ano5 may only be required under membrane damage (PMID:32455153) 5. GOF vs LOF — a knockout cannot model a gain-of-function allele

A limitation that applies to every mouse model: none reproduces the human jaw histopathology. "in mouse models, microscopic analysis revealed increased bone mineralization in the jaw lesions but not the microscopic features of fibrous-osseous lesions generally detected in patients with GDD." (PMID:37649308) Li et al. propose that large-animal models (horse, sheep, dog, pig) may be required (PMID:35982081).

Cellular and in vitro models

Notably absent: no patient-derived iPSC line, no bone organoid, no organ-on-chip, and no immortalized GDD patient osteoblast line. Riminucci's original 2001 work transplanted stromal cells grown from the jaw lesion into immunocompromised mice and achieved "a close mimicry of the native lesion" (PMID:11547842) — a xenograft model that, remarkably, has not been revisited in 25 years and represents an obvious opportunity.

Model resources

MGI (mouse Ano5), RIKEN BioResource Center (C57BL/6-Ano5^tm1Itak), and the investigator-generated lines B6-Ano5^tm1Pg/Uke, B6-Ano5^tm2Pg/Uke, B6-Ano5^tm3Pg/Uke (PolyGene AG / UKE Hamburg, PMID:32455153). No IMPC/KOMP GDD-relevant deep phenotyping has been published.

Curation notes for the dismech knowledge base

A few things that will bite whoever builds the YAML entry:

1. Named Entity Confusion risk is HIGH. ANO5 is far more famous for LGMDR12 / Miyoshi myopathy 3 than for GDD. A deep-research report, a dataset search, or a literature sweep keyed on "ANO5" will return predominantly muscular-dystrophy content that is coherent, correctly cited, and about the wrong disease. Run just preflight-dr <report> MONDO:0008151 before curating from any DR output. The specific facts most likely to leak across incorrectly: the c.191dupA northern European founder mutation, the 2:1–4:1 male predominance, the prevalence figures (0.27–2 per 100,000), and the 10–30% cardiac involvement — all of these belong to the recessive muscle disease and none applies to GDD.

2. Model the GOF/LOF dispute as competing mechanistic_hypotheses, not a single chain. Suggested groups: gain_of_function_scrambling (CANONICAL/ALTERNATIVE, per PMID:29124309, PMID:32112655) and loss_of_function_calcium_signaling (ALTERNATIVE, per PMID:35982081, PMID:28176803). Attach the two bone-mass subtypes to the respective groups.

3. Add a HUMAN_MODEL_MISMATCH discussion, not a generic KNOWLEDGE_GAP, for the mouse-model contradiction. Evidence exists in models; it is the translational validity that is contested. Use FAILS_TO_RECAPITULATE with mandatory limitations and evidence for the p.T491F knock-in (PMID:32455153).

4. Consider conforms_to targets. osteoporosis_bone_resorption#Increased Osteoclastic Bone Resorption is a poor fit — GDD osteoclastogenesis is largely decreased. A better fit may be defective_skeletal_mineralization (though GDD is over- rather than under-mineralization, so check the module's scope) and possibly loss_of_proteostasis for the misfolded-mutant-degradation arm. Do not force a conformance that the evidence does not support.

5. Lump/split decision on FGC and familial FCOD. Three independent lines of evidence (PMID:27216912, PMID:37649308, PMID:42361776) now place familial gigantiform cementoma and familial florid cemento-osseous dysplasia inside the ANO5 spectrum. Record the decision and reasoning explicitly.

6. Ontology terms flagged for OAK verification before binding: HP:0005045 (Diaphyseal cortical sclerosis), HP:0003621 (Juvenile onset), HP:0000006 (Autosomal dominant inheritance) — these came from the HPO API and are not in the repository's local cache/hp/terms.csv. An HPO term for elevated alkaline phosphatase was not found in the local cache and must be looked up. Every other HP, GO, CL, and UBERON identifier cited above was verified against the local ontology label caches.

Primary Sources

Disease definition and gene discovery - Riminucci M et al. Gnathodiaphyseal dysplasia: a syndrome of fibro-osseous lesions of jawbones, bone fragility, and long bone bowing. J Bone Miner Res 2001. PMID:11547842 - Tsutsumi S et al. Autosomal dominant gnathodiaphyseal dysplasia maps to chromosome 11p14.3-15.1. J Bone Miner Res 2003. PMID:12619924 - Tsutsumi S et al. The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD). Am J Hum Genet 2004. PMID:15124103 · DOI 10.1086/421527 - Mizuta K et al. Molecular characterization of GDD1/TMEM16E. Biochem Biophys Res Commun 2007. PMID:17418107

Clinical reports and variant discovery - Marconi C et al. Eur J Hum Genet 2013 (T513I, Italian pedigree). PMID:23047743 - Rolvien T et al. J Bone Miner Res 2017 (S500F, high-turnover osteosclerosis). PMID:27541832 - Jin L et al. Sci Rep 2017 (three novel variants; osteoblast studies). PMID:28176803 · DOI 10.1038/srep40935 - Otaify GA et al. Bone 2018 (G518E, severe atypical, pamidronate). PMID:29175271 - Zeng B et al. Head Neck 2019 (C356F; 67% misdiagnosis rate). PMID:30554457 - Marechal G et al. J Stomatol Oral Maxillofac Surg 2019 (R597I; reconstruction). PMID:30641283 - Sandal S et al. Congenit Anom 2021 (calvarial doughnut lesions). PMID:32902009 - Shaibani A et al. Neurol Genet 2021 (combined myopathy + GDD). PMID:34291158 · DOI 10.1212/NXG.0000000000000612 - Iranian family, C360R. Mol Genet Genomic Med 2022. PMID:35758145 - Cuvelier V et al. Prenat Diagn 2024 (two fetal cases + 108-patient literature review). PMID:38922934 · DOI 10.1002/pd.6631 - Long-term 41-year radiographic follow-up. Cureus 2025. PMID:40861765 - Double jaw surgery case report. J Craniomaxillofac Surg 2025. PMID:41193275

Nosology / jaw-lesion spectrum - Duong HY et al. Sci Rep 2016 (WES links dental tumour to ANO5). PMID:27216912 - Zhou Z et al. Mol Genet Genomic Med 2024 (FGC with C356Y). PMID:37649308 · DOI 10.1002/mgg3.2277 - Update on molecular pathology of fibro-osseous jaw lesions. Semin Diagn Pathol 2026. PMID:42361776

Mechanism — biophysics - Di Zanni E et al. Cell Mol Life Sci 2018 (T513I gain of function). PMID:29124309 · DOI 10.1007/s00018-017-2704-9 - Di Zanni E et al. Hum Mutat 2020 (GDD = GOF, MD = LOF). PMID:32112655

Mechanism — bone cell biology and models - Kim JH et al. Bone 2019 (Akt-NFATc1 osteoclast). PMID:30557634 - Wang X et al. Calcif Tissue Int 2019 (Ano5 KO replicates GDD). PMID:30712070 - Rolvien T et al. Bone Rep 2020 (p.T491F KI — no phenotype). PMID:32455153 - Li H et al. J Bone Miner Res 2022 (Cys360Tyr knock-in model). PMID:34841576 - Li X et al. NPJ Genom Med 2022 (calcium signalling; LOF subtype; PTH). PMID:35982081 · DOI 10.1038/s41525-022-00312-1 - Metabolomics/transcriptomics of Ano5^Cys360Tyr. Front Endocrinol 2023. PMID:36742392 - Liu X et al. Oral Dis 2024 (impaired osteoclastogenesis, NF-κB). PMID:36989132 - Akt signalling / SC79 rescue. Bone Rep 2025. PMID:39866532 - ER stress / CHOP osteoclast apoptosis. Exp Cell Res 2025. PMID:40049314 - ATG9A-dependent autophagy. JCI Insight 2025. PMID:40067389 - miR-34c-5p/KLF4/β-catenin. Int J Mol Sci 2025. PMID:40508076 - AMPK-dependent glucose metabolism. Front Endocrinol 2026. PMID:41717545

Management - Recurrent femoral shaft fractures in a child. BMC Musculoskelet Disord 2019. PMID:30797234 - Prosthodontic treatment, 30-year follow-up. Int J Prosthodont 2018. PMID:29518808 - Adult tibial shaft fracture. JBJS Case Connect 2021. PMID:33826556

Differential / context - Soontrapa P, Liewluck T. Anoctamin 5 (ANO5) muscle disorders: a narrative review. Genes 2022. PMID:36292621 - COL1A1 C-propeptide cleavage-site mutation as a GDD phenocopy. Clin Genet 2015. PMID:24891183 - GDD presenting as polyostotic fibrous dysplasia. Am J Med Genet A 2015. PMID:25866257

Databases - OMIM #166260 · OMIM *608662 - Orphanet ORPHA:53697 - MedlinePlus Genetics — gnathodiaphyseal dysplasia - Open Targets — MONDO_0008151 - MalaCards — gnathodiaphyseal dysplasia - GARD — gnathodiaphyseal dysplasia - LOVD ANO5 variant database - PubMed — gnathodiaphyseal dysplasia (56 results)

PubMed article metadata retrieved from PubMed (NCBI/NLM); DOIs are given inline for cited articles.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

10 of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

• PMID:11547842 (abstract only): "gnathodiaphyseal sclerosis"
• Text part not found as substring: 'gnathodiaphyseal sclerosis' (note: only abstract available for PMID:11547842, full text may contain this excerpt)
• PMID:12619924 (abstract only): "as a new and distinct disease entity from other systemic bone diseases"
• closest text in source: "Although GDD has been considered to be a variation of osteogenesis imperfecta (MIM 166260), our results indicate that this syndrome is a new and distinct disease entity from other systemic bone diseases"
• PMID:28176803: "severe facial disfigurement"
• Text part not found as substring: 'severe facial disfigurement'
• PMID:29175271 (abstract only): "severe facial disfigurement"
• Text part not found as substring: 'severe facial disfigurement' (note: only abstract available for PMID:29175271, full text may contain this excerpt)
• PMID:38922934 (abstract only): "probably pathogenic (class 4)"
• Text part not found as substring: 'probably pathogenic (class 4)' (note: only abstract available for PMID:38922934, full text may contain this excerpt)
• PMID:28176803: "fold with low efficiency and appear to be unstable and rapidly degraded via proteasomal degradation"
• closest text in source: "Recent studies23 suggest that mutant ANO5 protein (C356G and C356R) folds with low efficiency and appears to be unstable and rapidly degraded via proteasomal degradation"
• PMID:38922934 (abstract only): "multiple diaphyseal fractures of the long bones... affecting femurs, tibias, and bilateral upper extremity bones"
• closest text in source: "Clinical manifestations range from recurrent dental infections with mild jaw lesions to severe bone fragility with several fractures associated with large jaw lesions requiring disfiguring surgeries"
• PMID:24891183 (abstract only): "a new cause of gnathodiaphyseal dysplasia"
• closest text in source: "Gnathodiaphyseal dysplasia (GDD) is a rare autosomal dominant condition characterized by bone fragility, irregular bone mineral density (BMD) and fibro-osseous lesions in the skull and jaw"
• PMID:38922934 (abstract only): "symptoms can be very severe, even fatal"
• closest text in source: "Clinical manifestations range from recurrent dental infections with mild jaw lesions to severe bone fragility with several fractures associated with large jaw lesions requiring disfiguring surgeries"
• PMID:33826556 (abstract only): "successful callus formation"
• Text part not found as substring: 'successful callus formation' (note: only abstract available for PMID:33826556, full text may contain this excerpt)
• PMID:29518808 (abstract only): "despite severe alveolar bone resorption, prosthetic treatment improved patient satisfaction and functional ability, requiring regular adjustments and monitoring"
• closest text in source: "Despite the severe alveolar bone resorption, prosthodontic treatment improved the patient's satisfaction and ability to perform essential functions"
• PMID:38922934 (abstract only): "prenatal/pre-implantation diagnosis and medical termination should be discussed with couples"
• closest text in source: "A literature review was conducted to explore GDD's clinical and paraclinical presentation, diagnosis, and management"